Bristol Myers: Worries Create Opportunity

Bristol Myers Squibb Company sells at a low valuation due to worries over patent expirations. However, the company is working to replace the eventual revenue losses by developing its robust product pipeline while also acquiring new treatments.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.